# LCZ696 in Advanced LV Hypertrophy and HFpEF

> **NCT03928158** · PHASE2 · COMPLETED · sponsor: **National Medical Research Center for Cardiology, Ministry of Health of Russian Federation** · enrollment: 61 (actual)

## Conditions studied

- Heart Failure
- Essential Hypertension

## Interventions

- **DRUG:** LCZ 696
- **DRUG:** Valsartan

## Key facts

- **NCT ID:** NCT03928158
- **Lead sponsor:** National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-31
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03928158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03928158, "LCZ696 in Advanced LV Hypertrophy and HFpEF". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03928158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*